Clinical Trial

Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of adding the immunotherapy Avelumab as a fourth component, alongside tumor removal, chemotherapy, and radiation, to increase the chance of preserving the bladder in the treatment of muscle-invasive bladder cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-11.
Trial Details
NCT Number NCT06686381
Lead Sponsor American University of Beirut Medical Center
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Muscle-invasive Bladder Cancer
Enrollment 80 participants
Start Date 2025-04-15
Primary Completion 2028-08 (estimated)
Study Completion 2028-08-15 (estimated)
Updated on ClinicalTrials.gov 2025-02-05